Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 1.00 |
| ▸ | SRC | P12931 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7987551 | 0.99 | FGFR1 (0.97) | FGFR1SRCALDH1A1NPC1RAB9A | |
| SCHEMBL7993203 | 0.84 | FGFR1 (1.00) | FGFR1SRC | |
| Hydrochloric Acid SCHEMBL7987721 | 0.83 | FGFR1 (0.97) | FGFR1SRC | |
| SCHEMBL7986304 | 0.81 | FGFR1 (0.81) | FGFR1SRCALDH1A1 | |
| Hydrochloric Acid SCHEMBL7986271 | 0.80 | FGFR1 (0.80) | FGFR1SRCALDH1A1 | |
| SCHEMBL7989577 | 0.79 | FGFR1 (0.77) | FGFR1SRCALDH1A1 | |
| SCHEMBL23846263 | 0.79 | FGFR1 (0.76) | FGFR1SRCALDH1A1 | |
| Hydrochloric Acid SCHEMBL7986454 | 0.78 | FGFR1 (0.74) | FGFR1SRCALDH1A1 | |
| SCHEMBL122653 | 0.76 | FGFR1 (1.00) | FGFR1SRCALDH1A1NPC1RAB9A | |
| SCHEMBL30343716 | 0.76 | FGFR1 (1.00) | FGFR1SRCALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |